DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
GYKI 53655 hydrochloride (HB0312)
Description:Non-competitive AMPA receptor antagonist. Also blocks kainate GluK3 homomeric receptors.
Purity:>98%
-
Haloperidol hydrochloride (HB1842)
Description:Dopamine receptor antagonist with partial D2-like selectivity
Purity:>99%
-
Kynurenic acid (HB0362)
Description:Endogenous ionotropic glutamate / nicotinic antagonist.
Purity:>98%
-
LY-367385 hydrochloride (HB5153)
Description:Potent, highly selective mGlu1a antagonist. Water soluble.
-
-
-
-
MRS 2179 ammonium salt (HB4241)
Description:Selective P2Y1 antagonist. Inhibits platelet aggregation.
Purity:>98%
-
MTEP hydrochloride (HB0431)
Description:Potent, highly selective, non-competitive mGluR5 antagonist
Purity:>98%
